Archived Presentations | Regeneron Pharmaceuticals Inc.

INVESTORS & MEDIA

Archived Presentations

Jan 11 2021

Regeneron J.P. Morgan 2021 Presentation 1.7 MB

Dec 07 2020

Regeneron Oncology Investor Presentation, ASH 2020 1.3 MB

Nov 06 2020

Regeneron Corporate Presentation November 2020 1.4 MB

Oct 31 2020

Yancopoulos FOCIS Presentation 6.5 MB

Sep 29 2020

Regeneron COVID-19 Program Update 2 MB

Sep 08 2020

ERS 2020 Dupixent TRAVERSE LIBERTY ASTHMA LTS 466.8 KB

Aug 12 2020

Corporate Presentation August 2020 1.2 MB

Jun 12 2020

2020 Regeneron Shareholder Meeting Presentation 1.3 MB

Jun 12 2020

Phase 2 of Pozelimab in PNH 756.2 KB

Jun 09 2020

Corporate Presentation June 2020 1.2 MB

Jun 01 2020

Trial in Progress - Phase 1-2 for REGN5678 (PSMAxCD28) in mCRPC 1.3 MB

Jun 01 2020

Phase 2 of Libtayo in Advanced CSCC - Three-year follow-up 132 KB

Jun 01 2020

Trial in Progress - Phase 3 for Libtayo in Adjuvant CSCC 218.1 KB

Jun 01 2020

Regeneron Oncology Investor Event, ASCO 2020 Presentation 2.2 MB

Jun 01 2020

Trial in Progress - Phase 1-2 for REGN5093 (METxMET) in MET-Altered Advanced NSCLC 1.1 MB

Jun 01 2020

Phase 2 of Libtayo in Advanced CSCC - Post Hoc Exploratory Analysis 142.7 KB

Apr 06 2020

Change in Accounting Presentation Slide Deck 583.5 KB

Change in Accounting Presentation FAQ 189.7 KB

Mar 30 2020

ACC.20 - Evinacumab ELIPSE HoFH Ph3 1.9 MB

ACC.20 - Alirocumab Odyssey HoFH Ph3 1.3 MB

Mar 02 2020

Cowen 40th Annual Healthcare Conference Presentation 1.1 MB

Feb 09 2020

High-Dose Aflibercept - Rationale & Clinical Studies 3.1 MB

Ph 3 PANORAMA 100 Week Results 1.4 MB

Jan 13 2020

J.P. Morgan 2020 Presentation 2.6 MB

JP Morgan 2019 1.7 MB

Financial Overview 2019 505.7 KB

Financial Overview 2018 1.3 MB

2018 Cemiplimab Illustrative Example 26.6 KB

Financial Overview 2017 454.2 KB

Financial Overview 2016 791.6 KB

Financial Overview 2015 669.5 KB

Dec 08 2019

Phase 1 of REGN5458 (BCMAxCD3) in Relapsed/Refractory Multiple Myeloma 359.1 KB

Phase 1 of Pozelimab (REGN3918) in Normal Healthy Volunteers 415.8 KB

Study Design: Phase 2 of REGN1979 (CD3xCD20) in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) 148.4 KB

REGN1979 in patients with R/R B-NHL – ASH 2019 data update 991.9 KB

Nov 07 2019

Regeneron Oncology Strategy Presentation November 2019 565.1 KB

Sep 30 2019

Phase 2 of Neoadjuvant Cemiplimab in CSCC-HN (MD Anderson study) 8.8 MB

Jun 15 2019

REGN1979 in patients with R/R B-NHL 787.6 KB

Jun 01 2019

Phase 2 Cemiplimab in locally advanced CSCC – primary analysis 2 MB

Phase 1 of REGN3767 (LAG-3) and Cemiplimab 2.3 MB

Phase 2 Cemiplimab in metastatic CSCC – 12-month follow-up 348.4 KB

Apr 10 2019

Development of Novel Fully Human Bispecific Antibodies for Oncology 3 MB

Mar 01 2019

Phase 1 Cemiplimab NSCLC Monotherapy 348.5 KB

Phase 1 Cemiplimab Japanese Patients 358.5 KB

Phase 1 TPS Cemiplimab and REGN3767 (LAG-3) 1.5 MB

Feb 25 2019

Phase 3 SINUS-52 Study poster 679.8 KB

Phase 3 SINUS-24 Study presentation 531 KB

Feb 09 2019

Phase 3 PANORAMA 52 Week Data 20.6 MB

Dec 01 2018

View Presentation 789.4 KB

View Presentation 231.7 KB

Jul 24 2018

Phase 3 Panorama 24 Week Data - Wykoff 6.1 MB

Outcomes of Anti-VEGF for AMD in Clinical Practice - Moshfeghi 649.9 KB

Outcomes in DME w DPP-4 Inhibitors in VISTA and VIVID Trials - Rahimy 328.8 KB

Outcomes of AMD CNV VIEW Studies - Do 335.1 KB

Outcomes of Anti-VEGF for DME in Clinical Practice - Pitcher 614.4 KB

Phase 2 RUBY Trial - Heier 3.4 MB